Royal Bank of Canada
MGX icon

Royal Bank of Canada’s Metagenomi Therapeutics MGX Stock Holding History

Royal Bank of Canada’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
314
+291
+1,265% +$452 ﹤0.01% 7775
2025
Q4 		$0 Sell
23
-592
-96% -$1.28K ﹤0.01% 7725
2025
Q3 		$1K Buy
+615
New +$1.25K ﹤0.01% 7045
2025
Q2 		– Sell
-647
Closed -$1K – 7405
2025
Q1 		$1K Sell
647
-1,050
-62% -$2.5K ﹤0.01% 6731
2024
Q4 		$6K Buy
1,697
+777
+84% +$1.88K ﹤0.01% 6511
2024
Q3 		$2K Buy
920
+317
+53% +$1.1K ﹤0.01% 6667
2024
Q2 		$2K Buy
+603
New +$4.14K ﹤0.01% 6759

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada's MGX Position: Q1 2026 in Review

Royal Bank of Canada increased its Metagenomi Therapeutics (MGX) stake by 1,265% in Q1 2026, buying an estimated $452 and bringing the position to 314 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7775.

Royal Bank of Canada first reported a position in MGX in Q2 2024 and has held it in 7 quarters since. The position peaked at $6K in Q4 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Royal Bank of Canada held 314 shares of Metagenomi Therapeutics worth $0 as of Q1 2026.
  • Royal Bank of Canada bought 291 Metagenomi Therapeutics shares in Q1 2026, an estimated $452.
  • Metagenomi Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7775 holding.
  • Royal Bank of Canada first reported a position in Metagenomi Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Royal Bank of Canada's Metagenomi Therapeutics position peaked at $6K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.